VJOncology is committed to improving our service to you

ESMO 2019 | IMvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer

VJOncology is committed to improving our service to you

Thomas Powles

Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, discusses the data from the Phase III IMvigor130 trial (NCT02807636) being presented at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. This study evaluated atezolizumab monotherapy and atezolizumab with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter